The role of intraperitoneal therapy in advanced ovarian cancer

Lisa M. Hess, David S Alberts

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Intraperitoneal (IP) chemotherapy is a preferred treatment option that should be offered to all women for front-line treatment of stage III optimally debulked ovarian cancer. Patients should be provided with information on the survival and toxicity for both IP and intravenous (IV) therapies, as well as practical information about the administration of each regimen, so that they may play an active role in the decision-making process. When making a decision between IP and IV therapeutic options, the experience and preference of the oncologist are critical factors in determining appropriate therapy for each woman.

Original languageEnglish (US)
Pages (from-to)227-232
Number of pages6
JournalOncology (Williston Park, N.Y.)
Volume21
Issue number2
StatePublished - Feb 2007

Fingerprint

Ovarian Neoplasms
Decision Making
Therapeutics
Drug Therapy
Survival

ASJC Scopus subject areas

  • Oncology

Cite this

The role of intraperitoneal therapy in advanced ovarian cancer. / Hess, Lisa M.; Alberts, David S.

In: Oncology (Williston Park, N.Y.), Vol. 21, No. 2, 02.2007, p. 227-232.

Research output: Contribution to journalArticle

@article{523bb5bcbd634ec4b149146782b57248,
title = "The role of intraperitoneal therapy in advanced ovarian cancer",
abstract = "Intraperitoneal (IP) chemotherapy is a preferred treatment option that should be offered to all women for front-line treatment of stage III optimally debulked ovarian cancer. Patients should be provided with information on the survival and toxicity for both IP and intravenous (IV) therapies, as well as practical information about the administration of each regimen, so that they may play an active role in the decision-making process. When making a decision between IP and IV therapeutic options, the experience and preference of the oncologist are critical factors in determining appropriate therapy for each woman.",
author = "Hess, {Lisa M.} and Alberts, {David S}",
year = "2007",
month = "2",
language = "English (US)",
volume = "21",
pages = "227--232",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "2",

}

TY - JOUR

T1 - The role of intraperitoneal therapy in advanced ovarian cancer

AU - Hess, Lisa M.

AU - Alberts, David S

PY - 2007/2

Y1 - 2007/2

N2 - Intraperitoneal (IP) chemotherapy is a preferred treatment option that should be offered to all women for front-line treatment of stage III optimally debulked ovarian cancer. Patients should be provided with information on the survival and toxicity for both IP and intravenous (IV) therapies, as well as practical information about the administration of each regimen, so that they may play an active role in the decision-making process. When making a decision between IP and IV therapeutic options, the experience and preference of the oncologist are critical factors in determining appropriate therapy for each woman.

AB - Intraperitoneal (IP) chemotherapy is a preferred treatment option that should be offered to all women for front-line treatment of stage III optimally debulked ovarian cancer. Patients should be provided with information on the survival and toxicity for both IP and intravenous (IV) therapies, as well as practical information about the administration of each regimen, so that they may play an active role in the decision-making process. When making a decision between IP and IV therapeutic options, the experience and preference of the oncologist are critical factors in determining appropriate therapy for each woman.

UR - http://www.scopus.com/inward/record.url?scp=33847179097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847179097&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 227

EP - 232

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 2

ER -